Clinical trials: Methotrexate
RheumatoId Arthritis
RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis
RABIOPRED is an in vitro non-invasive blood test, which aims to identify patients with rheumatoid arthritis (RA) who are not likely to respond to anti-TNFα and methotrexate combination therapy.
- Trial name
- RABIOPRED (NCT03016260)
- Testing
- Infliximab, Adalimumab, Etanercept
- Where
- 8 sites in Czechia, France and 3 more
- Volunteers
- 250 people
- Sponsor
- TcLand Expression S.A.
Rheumatoid Arthritis
A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs
This open-label, single arm study will evaluate the effect of RoActemra/Actemra in combination with methotrexate on articular damage in the hand (synovitis/osteitis and erosions) in patients with moderate to severe rheumatoid…
- Trial name
- NCT01878318
- Testing
- methotrexate, tocilizumab [RoActemra/Actemra]
- Sponsor
- Hoffmann-La Roche
Systemic Lupus Erythematosus
Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus
This is a multi-center, open-label, phase I study.
- Trial name
- NCT05247203
- Testing
- Telitacicept, standard therapy
- Where
- 19 sites in China
- Volunteers
- 92 people
- Sponsor
- RemeGen Co., Ltd.
Rheumatoid Arthritis
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, active comparator (Cohort 1 only), parallel-group, dose-ranging study to evaluate the efficacy and safety of GDC-0853 in participants with moderate to…
- Trial name
- NCT02833350
- Testing
- GDC-0853, Adalimumab, Folic Acid
- Where
- 150 sites in United States, Argentina and 9 more
- Volunteers
- 578 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)
This study evaluates ATI-450 plus MTX versus placebo plus MTX in participants with moderate to severe active RA who have had an inadequate response to MTX alone.
- Trial name
- NCT05279417
- Testing
- ATI-450 50 mg oral tablet BID, Methotrexate, ATI-450 20 mg oral tablet BID
- Where
- 50 sites in United States, Bulgaria and 2 more
- Volunteers
- 251 people
- Sponsor
- Aclaris Therapeutics, Inc.